Aganirsen demonstrates significant activity in two models of wet AMD.

These data, published on-line in Investigative Ophthalmology & Visible Science , demonstrate the power of aganirsen to attain and exert activity on the retina. Related StoriesResearchers determine tumor suppressor genes that get subset of melanomasImproved gene therapy treatment displays guarantee in mice with cystic fibrosisRNA-based drugs provide many advantages over CRISPR/Cas9 gene editing program Age-related macular degeneration and ischemic retinopathies are significant reasons of blindness that are associated with neovascularisation. This can result in sub-retinal and intravitreal hemorrhage, and retinal detachment tragically, which in turn causes blindness, explained lead author Dr. For the first time in this study, we’ve demonstrated that IRS-1, an angiogenic protein, is certainly expressed in the retina and that aganirsen is able to effectively attenuate neovascularization by inhibiting IRS-1 expression, without impacting normal vascularisation, noted co-lead author Dr.Fluorescein angiography and fundus autofluorescence imaging at 12 weeks after therapy showed no significant differ from baseline in any participant . Retinal Thickness Of the 10 eye where subretinal vector administration involved the fovea , 6 had a sustained decrease in macular thickness . Macular thinning was typically apparent within three months and subsequently was relatively stable. Associated thinning of the photoreceptor-cell coating was evident, with variable disruption of the photoreceptor ellipsoid zone .